1. Home
  2. QCLS vs MBIO Comparison

QCLS vs MBIO Comparison

Compare QCLS & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Q/C Technologies Inc.

QCLS

Q/C Technologies Inc.

N/A

Current Price

$0.43

Market Cap

3.7M

Sector

Health Care

ML Signal

N/A

MBIO

Mustang Bio Inc.

N/A

Current Price

$0.41

Market Cap

4.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QCLS
MBIO
Founded
2014
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7M
4.1M
IPO Year
2013
2023

Fundamental Metrics

Financial Performance
Metric
QCLS
MBIO
Price
$0.43
$0.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 184.3K
36.0K
Earning Date
11-18-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
22.33
★ 98.99
EPS
N/A
★ N/A
Revenue
★ $3,929,527.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$405.45
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 32.71
N/A
52 Week Low
$0.42
$0.35
52 Week High
$8.17
$1.45

Technical Indicators

Market Signals
Indicator
QCLS
MBIO
Relative Strength Index (RSI) 26.07 47.56
Support Level $0.42 N/A
Resistance Level $1.18 $0.56
Average True Range (ATR) 0.05 0.03
MACD 0.04 0.01
Stochastic Oscillator 7.71 76.14

Price Performance

Historical Comparison
QCLS
MBIO

About QCLS Q/C Technologies Inc.

Q/C Technologies Inc is engaged in building blockchain and cryptocurrency infrastructure that is faster and more energy-efficient through quantum-class laser-based computing. The company uses laser-based processors inspired by quantum technology that can solve complex problems. By combining photonic computing with cryptocurrency systems, the company creates powerful and sustainable solutions for the next generation of blockchain applications.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: